	US 12,263,231 B2
	Adeno-associated virus virions for treatment of epilepsy
Shin-ichi Muramatsu, Tochigi (JP); Keiji Oguro, Tochigi (JP); and Kuniko Shimazaki, Tochigi (JP)
Assigned to Jichi Medical University, Tochigi (JP); and Gene Therapy Research Institution Co., Ltd., Kawasaki (JP)
Filed by Jichi Medical University, Tochigi (JP); and Gene Therapy Research Institution Co., Ltd., Kawasaki (JP)
Filed on Apr. 29, 2022, as Appl. No. 17/732,901.
Application 17/732,901 is a division of application No. 16/069,370, abandoned, previously published as PCT/JP2017/001048, filed on Jan. 13, 2017.
Prior Publication US 2022/0275399 A1, Sep. 1, 2022
Int. Cl. A61K 48/00 (2006.01); A61K 35/761 (2015.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61P 25/08 (2006.01); A61P 25/28 (2006.01); C07K 14/705 (2006.01); C12N 15/864 (2006.01)

CPC A61K 48/005 (2013.01) [A61K 35/761 (2013.01); A61K 38/177 (2013.01); A61K 45/06 (2013.01); A61K 48/0075 (2013.01); A61P 25/08 (2018.01); A61P 25/28 (2018.01); C07K 14/705 (2013.01); C12N 15/8645 (2013.01); A61K 48/0058 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01)]

6 Claims

1. A method for reduction in intensity, duration or frequency of seizures due to epilepsy in a subject, which comprises administrating by intracranial or intracardiac administration to the subject a pharmaceutical composition comprising a recombinant adeno-associated virus vector, wherein the vector comprises:

a polynucleotide comprising a nucleotide sequence encoding a neuroligin 2 protein which comprises the amino acid sequence of SEQ ID NO: 2, 4 or 6, and

a capsid protein having a variant amino acid sequence which has the amino acid sequence of SEQ ID NO:11, and optionally one or more tyrosine residues in the sequence substituted with phenylalanine.